Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drink that turns to gel in your stomach could curb hunger

NCT ID NCT07127198

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested three versions of a protein-and-fiber drink that turns into a gel in the stomach, to see if it reduces appetite. Twenty-four adults with a BMI between 27 and 32 each tried the drinks and a control on separate days. Researchers measured how full they felt and checked their hunger hormones and food intake later in the day.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
protein and fiber drink
What this could lead to
If it works, this could point toward a simple drink that helps people feel fuller and manage their weight without drugs.
What could go wrong
This is a small, early study with only 24 people, so results may not apply widely. The effect on appetite may be small or temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

May 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or Female aged 18-65 years old (inclusive) 2. Body Mass Index (BMI) 27 - 32kg/m2 (inclusive), measured and defined by the site 3. Self-reported stable body weight for the past 6 months prior to screening (defined as not having gained or lost more than 5% of body weight) 4. Comfortable using technology, such as a smartphone or laptop 5. Willing and able to understand and sign a written informed consent prior to study entry 6. Deemed able to comply with the requirements of the study protocol and consume study products by study nurse Exclusion Criteria: 1. Currently or in the last 3 months, use of medications affecting weight, study outcomes, including fat absorption such as, but not limited to: GLP-1 receptor analogues, SGLT-2 inhibitors, weight loss medications, medications that affect gastric pH, and any of the following drugs: cephaloridine, verapamil, valproic acid, and sulfonylureas, usually acting by competitive inhibition of L-carnitine transport by OCTN2, Orlistat, antacids, proton pump inhibitors, antibiotics, steroids or medications affecting thyroid hormones or gut hormones, antipsychotic medications, or antidepressants. As reported by participant. 2. Diagnosed with Eating behaviour disorders such as emotional or restrained eating determined or any ongoing psychiatric illness. As reported by participant. 3. Currently or within the last 3 months or planning to during the course of the study being on a weight loss regime (defined by actively following a diet such as Atkins, weight watchers, meal replacements, low or very low carbohydrate diet, ketogenic diet, intermediate fasting or enrolled into a governmental health program) or applying significant restrictions on food intake (i.e., regular breakfast skipping, regular cut on carbohydrates, regular intermittent fasting, diet reducing a specific macronutrient, diet significantly reducing calorie intake, excluding a group of food that was not excluded before). As reported by participant. 4. Any known/suspected food allergies. As reported by participant. 5. Currently pregnant, lactating, or breastfeeding. As reported by participant. 6. Unstable diagnosed chronic conditions (such as hypertension, cardiovascular diseases, liver diseases, renal diseases, metabolic diseases). Unstable is defined as a change in medications in the past 3 months, or a change in disease severity in the past 3 months. As reported by participant. 7. Acute GI upset (such as diarrhoea/constipation in the last 2 weeks, abdominal cramping etc.). As reported by participant. 8. Diagnosed with chronic GI disorder such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, or irritable bowel syndrome. As reported by participant. 9. Ever underwent surgery for weight loss such as bariatric procedures or gastric bypass. As reported by participant. 10. Recent blood donation (\<8 weeks). As reported by participant. 11. Current or past smokers (stopped less than 3 months ago). As reported by participant. 12. Any drug abuse within the past year. As reported by participant. 13. Alcohol consumption above levels recommended for healthy adults: Average alcohol intake \> 2 standard drinks per day over a week for males or \> 1 standard drink per day over a week for females as reported by the participant. One standard drink contains 10-12 g of ethanol, i.e., 0.3 dl of strong alcohols, 1dl of wine, 3 dl of beer. As reported by participant. 14. Currently participating in another interventional study. As reported by participant. 15. Family or hierarchical relationships with the research team members. As reported by participant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Weight management are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Body Weight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Innovation Lab - Nestlé Research

    Lausanne, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.